来源：Gangtise投研

　　基石药业（02616.HK）2024年度业绩交流会：2024年上半年，基石药业总收入达到人民币2.542亿元，其中包括药品销售收入1.183亿元（阿伐替尼和普拉替尼），授权费收入1.226亿元，以及舒格利单抗特许权使用费收入1330万元。公司首次实现盈利，净利润近1600万元，财务状况稳健，现金储备为8.14亿元人民币。2024年全年，基石药业收入为4.07亿元，同比减少12.21%，但亏损大幅减少至9120.7万元，同比减少75.16%。公司成功上市4款创新药，并获得涵盖9个适应症的16项NDA批准。舒格利单抗在欧盟获批，成为首个成功出海的国产PD-L1单抗，与Ewopharma达成商业化战略合作，预计2025年初开始进入欧洲及其他海外市场销售。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：王若云

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.